ALB and non-small cell lung carcinoma: Turner et al. discovered that patients with clinical features of cancer cachexia, such as excessive weight loss and albumin loss, had a faster clearance of pembrolizumab, and faster clearance was associated with shorter OS in patients with advanced melanoma and non-small cell lung carcinoma [52].